News | August 30, 2023
Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Subscribe To Our Newsletter & Stay Updated
